Fig. 1: A single dose of PA-915 ameliorated the increased immobility time in the forced swim test (FST) in repeated corticosterone-induced depression mice and social isolation-reared mice.

(A) The immobility time in the FST in male and female repeated corticosterone-induced depression mice that received PA-915 [30 mg/kg, intraperitoneally (i.p.)] or vehicle treatment and naïve control mice. Statistical significance was assessed using one-way analysis of variance (ANOVA; n = 8–13; male, F(2, 32) = 22.49, p < 0.01; female, F(2, 22) = 11.48, p < 0.01) followed by the Tukey-Kramer test. (B) The immobility time in the FST in male repeated corticosterone-induced depression mice injected with PA-915 at the indicated doses ranging from 0.001 to 30 mg/kg, i.p. or vehicle. Statistical significance was assessed using one-way ANOVA (n = 5–11, F(6, 57) = 88.97, p < 0.01) followed by the Dunnett’s test. (C) The immobility time in the FST in male social isolation-reared mice that received PA-915 (30 mg/kg, i.p.) or vehicle treatment and naïve control mice. Statistical significance was assessed using one-way ANOVA (n = 13–16, F(2, 40) = 4.56, p = 0.016) followed by the Tukey-Kramer test. *p < 0.05, **p < 0.01. The values are expressed as means ± SEM from two independent experiments.